Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | PPM1D | O15297 | 1/20 | 0.32 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3832181 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL29203075 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL18577100 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL239646 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL2809688 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL3832206 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL2708045 | 0.88 | UCHL1 (0.39) | ATMPPM1DUCHL1 | |
| SCHEMBL15203438 | 0.87 | ATM (0.36) | ATMPPM1D | |
| SCHEMBL28776789 | 0.87 | ATM (0.36) | ATMPPM1D | |
| SCHEMBL3528010 | 0.87 | ATM (0.36) | ATMPPM1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | ONCODESIGN S.A. (FR) | 2026-05-19 | — | — | US | disclosed |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN S.A. (FR) | 2026-05-07 | — | — | US | disclosed |
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2024-08-01 | — | — | US | disclosed |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | ONCODESIGN SA (FR) | 2023-04-27 | — | — | US | disclosed |
| EP-4097110-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | Oncodesign S.A. (FR) | 2022-12-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240254140-A1 | COMPOUNDS AND THEIR USE IN THE TREATMENT OF BACTERIAL INFECTION | C3AR1, LTB4R, C5 | TSHR 1801/4885ATM 3666/4885PPM1D 3443/4885 |
| US-20260125396-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK1, RIPK2, RIPK4 | TSHR 1770/4885ATM 2809/4885PPM1D 903/4885 |
| US-12630563-B2 | Macrocyclic RIP2-kinase inhibitors | RIPK1, RIPK2, RIPK3 | TSHR 2985/4885ATM 2546/4885PPM1D 396/4885 |
| US-20230126352-A1 | MACROCYCLIC RIP2-KINASE INHIBITORS | RIPK2, RIPK1, RIPK3 | TSHR 3830/4885ATM 751/4885PPM1D 949/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.